Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
53 Leser
Artikel bewerten:
(0)

Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences

LONDON, July 31, 2014 /PRNewswire/ --

On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:

http://investor-edge.com/register

On Wednesday, IsoRay Inc.'s stock recorded a trading volume of 0.81 million shares, lower than its three months average volume of 2.83 million shares. The stock finished the day flat at the previous day's closing price of $2.55, and registered an intraday range of $2.50 and $2.58. Shares of IsoRay Inc. have declined 18.27% in the last one month. However, the stock has rallied 5.81% in the previous three months and 410.00% on YTD basis. Furthermore, the company's shares are trading above its 200-day moving average. The stock's 50-day moving average of $2.62 is above its 200-day moving average of $1.52. Additionally, shares of IsoRay Inc. have a Relative Strength Index (RSI) of 40.94. Sign up and read the free notes on ISR at:

http://www.Investor-Edge.com/ISR-31Jul2014

Neurocrine Biosciences Inc.'s stock advanced 2.19%, to close Wednesday's session at $14.00, after oscillating between $13.74 and $14.16. The stock recorded a trading volume of 0.45 million shares, below its three months average volume of 0.52 million shares. Over the last one month and past three months, Neurocrine Biosciences Inc.'s shares have lost 5.63% and 0.14%, respectively. However, from the beginning of 2014, the stock has surged 49.89%. The stock is trading above its 200-day moving average. The stock's 50-day moving average of $14.25 is above its 200-day moving average of $13.74. Further, Neurocrine Biosciences Inc.'s stock has an RSI of 46.44. The complimentary notes on NBIX can be downloaded as in PDF format at:

http://www.Investor-Edge.com/NBIX-31Jul2014

On Wednesday, OPKO Health Inc.'s stock finished the session 1.22% lower at $8.94. A total of 1.68 million shares were traded, which was below its three months average volume of 2.39 million shares. The stock moved between $8.91 and $9.19 during the session. Over the last one month and past three months, OPKO Health Inc.'s shares have gained 1.13% and 8.10%, respectively. Also, the stock has advanced 5.92% since the start of this year. The company's shares are trading above their 50-day moving average. Moreover, the stock's 200-day moving average of $9.15 is greater than its 50-day moving average of $8.88. OPKO Health Inc.'s stock has an RSI of 55.41. Register for free on Investor-Edge and access the latest research on OPK at:

http://www.Investor-Edge.com/OPK-31Jul2014

Shares in Orexigen Therapeutics Inc. fluctuated between $4.95 and $5.13 before ending Wednesday's session down 2.12%, at $5.08. The stock reported a trading volume of 4.28 million shares, above its three months average volume of 3.40 million shares. Further, shares of Orexigen Therapeutics Inc. have plummeted 17.80% over the last one month and 9.61% over the past three months. Also, the stock has fallen by 9.77% on YTD basis. The company's shares are trading below their 50-day and 200-day moving averages. The stock's 200-day moving average of $6.00 is greater than its 50-day moving average of $5.84. Moreover, shares of Orexigen Therapeutics Inc. have an RSI of 39.18. The complete research on OREX is available for free at:

http://www.Investor-Edge.com/OREX-31Jul2014

Gilead Sciences Inc.'s stock gained 0.86%, to close Wednesday's session at $93.79, after hitting 52-week high of $94.34. The stock recorded a trading volume of 10.75 million shares, below its three months average volume of 11.74 million shares. Over the last one month and past three months, Gilead Sciences Inc.'s shares have surged 13.12% and 19.49%, respectively. Also, from the beginning of 2014, the stock has gone up 24.89%. The stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $84.32 is above its 200-day moving average of $77.13. Further, Gilead Sciences Inc.'s stock traded at a PE ratio of 20.75 and has an RSI of 70.14. Free in depth research on GILD is available at:

http://www.Investor-Edge.com/GILD-31Jul2014

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Investor-Edge.com

SOURCE Investor-Edge

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.